Navigation Links
Today's Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
Date:6/20/2013

LONDON, June 20, 2013 /PRNewswire/ --

The U.S. Supreme Court's decision last week on human gene patents is likely to have a major impact on the biotechnology industry, especially on smaller companies. The Supreme Court last week ruled that a naturally occurring DNA segment is a product of nature, and not patent-eligible just because it has been isolated. On Wednesday, June 19, 2013, shares in biotechnology companies ended mostly lower, tracking losses in the broader market, which fell sharply after market participants digested comments from Federal Reserve Chairman Ben Bernanke. The major movers in the sector included Inovio Pharmaceuticals Inc. (AMEX: INO), Sequenom Inc. (NASDAQ: SQNM), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), and Optimer Pharmaceuticals Inc. (NASDAQ: OPTR). AAAResearchReports.com have completed their technical analysis on INO, SQNM, PPHM, ONXX, and OPTR and these free reports are accessible by registering at

http://www.aaaresearchreports.com/register/  

Shares in Inovio Pharmaceuticals Inc. moved lower on Wednesday, reversing some of their gains from earlier in the week. The company's shares traded between $0.66 and $0.70 before finishing the day 0.57% lower at $0.69. A total of 758,372 shares were traded which is below the daily average volume of 1.36 million. Shares of INO are now up more than 3.70% for this week. Sign up for free technical research on INO at:

http://www.AAAResearchReports.com/INO062013.pdf

Sequenom Inc.'s stock moved higher yesterday even as the broader market struggled. The company's shares traded between $4.18 and $4.37 before finishing the day 0.72% higher at $4.22. A total of 1.69 million shares were exchanged which is below the daily average volume of 2.53 million. However, despite the gains, Sequenom's shares are down 3.87% so far this week. Be sure to read our latest technical research on SQNM by registering at:

http://www.AAAResearchReports.com/SQNM062013.pdf

Shares in Peregrine Pharmaceuticals fell on Wednesday, tracking losses in the broader market. The company's shares hit an intraday low of $1.46 before finishing the day 1.33% lower at $1.48. A total of 1.04 million shares were traded which is below the daily average volume of 3.19 million. Peregrine's shares have recently slipped below their 50-day and 200-day moving averages. Sign up and read the complimentary report on PPHM at:

http://www.AAAResearchReports.com/PPHM062013.pdf

Onyx Pharmaceuticals Inc.'s stock fell sharply on Wednesday, extending its losses for the week. The company's shares ended the day 3.67% lower at $85.54 after trading between $85.45 and $88.80. A total of 960,263 shares were traded which is below the daily average volume of 1.16 million. Onyx's shares have now fallen more than 5% in the last three trading sessions. The stock is currently trading below its 50-day moving average. The free report on ONXX can be downloaded by signing up now at:

http://www.AAAResearchReports.com/ONXX062013.pdf

Shares in Optimer Pharmaceuticals Inc. fell yesterday, tracking losses in the broader market. The company's shares ended the day 0.76% lower at $14.33 after trading between $14.25 and $14.61. A total of 459,088 shares were traded which is below the daily average volume of 1.12 million. Optimer's shares have now fallen over 1.50% so far this week. In the last three months, the stock has gained over 17.60%, thus outperforming the S&P 500. Shares of the company are currently trading slightly below their 50-day moving average. A free report on OPTR can be accessed by registering at:

http://www.AAAResearchReports.com/OPTR062013.pdf

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


'/>"/>
SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
2. New Research: Nationwide Report Shows Prescribed Drugs Not Detected in More Than One-Third of Pain Patient Samples
3. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
4. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
5. Inovio Pharmaceuticals to Present at SPI 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Inovio Pharmaceuticals to Present at JMP Investor Conference
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
10. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):